Securities Registration (section 12(b)) (8-a12b)

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

 

FORM 8-A

 

 

FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES

PURSUANT TO SECTION 12(b) OR (g) OF

THE SECURITIES EXCHANGE ACT OF 1934

 

 

 

GlaxoSmithKline plc		GlaxoSmithKline Capital plc
(Exact name of registrant as specified in its charter)		(Exact name of registrant as specified in its charter)
England and Wales		England and Wales
(Jurisdiction of incorporation or organization)		(Jurisdiction of incorporation or organization)
98-0607772		Not Applicable
(I.R.S. Employer Identification No.)		(I.R.S. Employer Identification No.)
980 Great West Road, Brentford Middlesex TW8 9GS, England		980 Great West Road, Brentford Middlesex TW8 9GS, England
(Address of principal executive offices)		(Address of principal executive offices)

Securities to be registered pursuant to Section 12(b) of the Act:

 

Title of each class to be so registered		Name of each exchange on which each class is to be registered
2.875% Notes due 2022 3.000% Notes due 2024 3.375% Notes due 2029		New York Stock Exchange New York Stock Exchange New York Stock Exchange

 

 

If this form relates to the registration of a class of securities pursuant to Section 12(b) of the Exchange Act and is effective pursuant to General Instruction A.(c), please check the following box.  ☒

If this form relates to the registration of a class of securities pursuant to Section 12(g) of the Exchange Act and is effective pursuant to General Instruction A.(d), please check the following box.  ☐

Securities Act registration statement file numbers to which this form relates:

333-223982; 333-223982-02

Securities to be registered pursuant to Section 12(g) of the Act:

None

(Title of class)

 

 

 

---

Item 1.

Description of Registrants’ Securities to be Registered.

For a description of the securities to be registered hereunder, reference is made to the information under the heading “Description of Debt Securities” on pages 9 through 20 of the Prospectus dated March 28, 2018 included in the registration statement on Form F-3 (Registration Nos. 333-223982 and 333-223982-02) of GlaxoSmithKline plc and GlaxoSmithKline Capital plc, as supplemented by the information under the heading “Description of the Notes” on pages S-14 through S-21 of the related Prospectus Supplement, dated March 18, 2019, which information is incorporated by reference and made part of this registration statement in its entirety.

 

Item 2.

Exhibits.

The securities to be registered hereunder are expected to be listed on the New York Stock Exchange, the exchange on which certain other securities of GlaxoSmithKline plc and GlaxoSmithKline Capital plc are currently registered. Pursuant to the Instructions as to Exhibits with respect to Form 8-A, the following exhibits are being filed with the Securities and Exchange Commission in connection with this Registration Statement:

 

1.1.		Prospectus dated March 28, 2018 and Prospectus Supplement dated March 18, 2019 incorporated by reference to the registrants’ filing under Rule 424(b)(2) dated March 18, 2019 (Registration Nos. 333-223982 and 333-223982-02).
1.2		Indenture, dated as of April 6, 2004, among GlaxoSmithKline Capital plc, GlaxoSmithKline plc, as guarantor, and Deutsche Bank Trust Company Americas, as trustee (as successor to Law Debenture Trust Company of New York, pursuant to an Instrument of Resignation, Appointment and Acceptance dated April 12, 2017, among GlaxoSmithKline Capital plc, Law Debenture Trust Company of New York and Deutsche Bank Trust Company Americas)(the “trustee”), incorporated by reference to Exhibit 4.4 of the registrants’ Report of Foreign Issuer on Form 6-K (File No. 001-15170), filed with the Securities and Exchange Commission on April 7, 2004.
1.3		First Supplemental Indenture, dated as of March 21, 2014, among GlaxoSmithKline Capital plc, GlaxoSmithKline plc, as guarantor, and the trustee, incorporated by reference to Exhibit 4.7 of the registrants’ Registration Statement on Form F-3 (File Nos. 333-217125, and 333-217125-02), filed with the Securities and Exchange Commission on April 3, 2017.
1.4		Second Supplemental Indenture dated as of May 15, 2018 among GlaxoSmithKline Capital plc, GlaxoSmithKline plc, as guarantor, and the trustee, incorporated by reference to Exhibit 4.1 to the registrants’ Report of Foreign Issuer on Form 6-K (File No. 001-15170), filed with the Securities and Exchange Commission on May 15, 2018.
1.5		Form of Global Note for 2.875% Notes due 2022.
1.6		Form of Global Note for 3.000% Notes due 2024.
1.7		Form of Global Note for 3.375% Notes due 2029.

---

SIGNATURE

Pursuant to the requirements of Section 12 of the Securities Exchange Act of 1934, each of the registrants has duly caused this registration statement or amendment thereto to be signed on its behalf by the undersigned, thereunto duly authorized.

 

GLAXOSMITHKLINE CAPITAL PLC
By:		/s/ Victoria Whyte

Name:		Victoria Whyte
Title:		Company Secretary

 

GLAXOSMITHKLINE PLC
By:		/s/ Victoria Whyte

Name:		Victoria Whyte
Title:		Company Secretary

Date: March 25, 2019

[Signature page to Form 8-A]

---

INDEX TO EXHIBITS

 

Exhibit No.		Exhibit
1.1		Prospectus dated March 28, 2018 and Prospectus Supplement dated March 18, 2019 incorporated by reference to the registrants’ filing under Rule 424(b)(2) dated March 18, 2019 (Registration Nos. 333-223982 and 333-223982-02).
1.2		Indenture, dated as of April 6, 2004, among GlaxoSmithKline Capital plc, GlaxoSmithKline plc, as guarantor, and Deutsche Bank Trust Company Americas, as trustee (as successor to Law Debenture Trust Company of New York, pursuant to an Instrument of Resignation, Appointment and Acceptance dated April 12, 2017, among GlaxoSmithKline Capital plc, Law Debenture Trust Company of New York and Deutsche Bank Trust Company Americas)(the “trustee”), incorporated by reference to Exhibit 4.4 of the registrants’ Report of Foreign Issuer on Form 6-K (File No. 001-15170), filed with the Securities and Exchange Commission on April 7, 2004.
1.3		First Supplemental Indenture, dated as of March 21, 2014, among GlaxoSmithKline Capital plc, GlaxoSmithKline plc, as guarantor, and the trustee, incorporated by reference to Exhibit 4.7 of the registrants’ Registration Statement on Form F-3 (File Nos. 333-217125, and 333-217125-02), filed with the Securities and Exchange Commission on April 3, 2017.
1.4		Second Supplemental Indenture dated as of May 15, 2018 among GlaxoSmithKline Capital plc, GlaxoSmithKline plc, as guarantor, and the trustee, incorporated by reference to Exhibit 4.1 to the registrants’ Report of Foreign Issuer on Form 6-K (File No. 001-15170), filed with the Securities and Exchange Commission on May 15, 2018.
1.5		Form of Global Note for 2.875% Notes due 2022.
1.6		Form of Global Note for 3.000% Notes due 2024.
1.7		Form of Global Note for 3.375% Notes due 2029.